ダウンロード数: 161

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
16_0619.pdf328.17 kBAdobe PDF見る/開く
タイトル: Double Blind法によるRifampicinの検討
その他のタイトル: A double blind study of rifampicin
著者: 西浦, 常雄  KAKEN_name
田村, 公一  KAKEN_name
上野, 一恵  KAKEN_name
二宮, 敬宇  KAKEN_name
神谷, 春子  KAKEN_name
著者名の別形: Nishiura, Tsuneo
Tamura, Masakazu
Ueno, Kazue
Ninomiya, Keiu
Kamiya, Haruko
キーワード: Cephalosporins/therapeutic use
Clinical Trials as Topic
Drug Resistance, Microbial
Humans
Piperidines/therapeutic use
Rifampin/administration & dosage/adverse effects/therapeutic use
Urinary Tract Infections/drug therapy
発行日: Oct-1970
出版者: 京都大学医学部泌尿器科学教室
誌名: 泌尿器科紀要
巻: 16
号: 10
開始ページ: 619
終了ページ: 623
抄録: A double blind study was made on rifampicin (RFP) and cephaloglycin (CEG) for 55 nonspecific urinary tract infections. RFP was administered 900 mg/day (b. i. d.) and CEG 2 g/day (q. i. d.), each for three days. Of 42 acute cystitis, 23 were treated with RPF and a11 responded, whereas 19 were treated with CEG and 17 responded (Table 2). There was, however, no statistically significant difference between the effectiveness rate of both drugs (p=O.1988). Out of 13 cases of urinary tract infection other than acute cystitis, 6 were treated with RFP and 3 were cured while 7 with CEG and 4 cured (Table 3). MIC of RFP for the isolated organisms from the cases above mostly ranged between 6.25 and 25 mcg/ml (Table 5). Disappearance rate of urinary microorganism after drug administration for acute cystitis was 96 % CZZ/Z3) in RFP-group and 63 % (12/19) in CEG-group. This shows superiority of RFP (p=O.0098). Even after three days' administration, increased RFP-resistance was proved in 4 strains (Table 7). No side-effects were encountered.
URI: http://hdl.handle.net/2433/121174
PubMed ID: 4920593
出現コレクション:Vol.16 No.10

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。